X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (129320) 129320
Book Review (28047) 28047
Publication (11657) 11657
Conference Proceeding (429) 429
Newsletter (425) 425
Book Chapter (392) 392
Newspaper Article (392) 392
Book / eBook (362) 362
Magazine Article (284) 284
Government Document (112) 112
Dissertation (100) 100
Web Resource (48) 48
Trade Publication Article (17) 17
Paper (11) 11
Data Set (10) 10
Streaming Video (10) 10
Presentation (9) 9
Reference (5) 5
Video Recording (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (120318) 120318
index medicus (118873) 118873
female (89833) 89833
oncology (60156) 60156
breast neoplasms - drug therapy (50853) 50853
breast cancer (47418) 47418
middle aged (38544) 38544
cancer (38023) 38023
breast neoplasms - pathology (31392) 31392
aged (29429) 29429
adult (29233) 29233
breast-cancer (28897) 28897
animals (28822) 28822
cell line, tumor (23365) 23365
chemotherapy (22298) 22298
male (18990) 18990
breast neoplasms - metabolism (16633) 16633
mice (16426) 16426
care and treatment (15429) 15429
research (15289) 15289
metastasis (14982) 14982
antineoplastic agents - therapeutic use (14559) 14559
tumors (14384) 14384
prognosis (14288) 14288
apoptosis (13725) 13725
antineoplastic combined chemotherapy protocols - therapeutic use (13556) 13556
expression (13475) 13475
treatment outcome (12836) 12836
breast neoplasms - genetics (12602) 12602
therapy (11999) 11999
health aspects (11776) 11776
analysis (11403) 11403
antineoplastic agents - pharmacology (11169) 11169
neoplasms - drug therapy (9819) 9819
pharmacology & pharmacy (9747) 9747
medicine & public health (9416) 9416
aged, 80 and over (9234) 9234
gene expression (9216) 9216
cell biology (8897) 8897
risk factors (8612) 8612
carcinoma (8599) 8599
biochemistry & molecular biology (8497) 8497
article (8480) 8480
proteins (8412) 8412
cancer therapies (8269) 8269
apoptosis - drug effects (8130) 8130
cell proliferation - drug effects (8095) 8095
survival (8094) 8094
neoplasm metastasis (8092) 8092
breast neoplasms - surgery (7816) 7816
genetic aspects (7740) 7740
neoplasm staging (7600) 7600
chemotherapy, adjuvant (7463) 7463
abridged index medicus (7339) 7339
gene expression regulation, neoplastic (7307) 7307
breast neoplasms - therapy (7295) 7295
drug therapy (7243) 7243
research article (7237) 7237
medicine (7117) 7117
cells (7025) 7025
tamoxifen (6948) 6948
breast neoplasms - mortality (6732) 6732
women (6732) 6732
development and progression (6669) 6669
signal transduction (6627) 6627
immunohistochemistry (6465) 6465
growth (6412) 6412
surgery (6385) 6385
breast (6378) 6378
mice, nude (6232) 6232
dose-response relationship, drug (5988) 5988
disease-free survival (5931) 5931
time factors (5816) 5816
tumor cells, cultured (5808) 5808
trastuzumab (5792) 5792
retrospective studies (5707) 5707
tamoxifen - therapeutic use (5629) 5629
hematology, oncology and palliative medicine (5626) 5626
in-vitro (5454) 5454
combined modality therapy (5301) 5301
cancer research (5275) 5275
oncology, experimental (5230) 5230
cell proliferation (5123) 5123
drug resistance, neoplasm (5123) 5123
xenograft model antitumor assays (5112) 5112
kinases (5082) 5082
estrogen (5073) 5073
multidisciplinary sciences (5066) 5066
medicine, research & experimental (4967) 4967
survival analysis (4923) 4923
studies (4916) 4916
antineoplastic agents - administration & dosage (4903) 4903
neoplasms - pathology (4895) 4895
antineoplastic combined chemotherapy protocols - adverse effects (4874) 4874
postmenopausal women (4866) 4866
follow-up studies (4844) 4844
prostate-cancer (4814) 4814
clinical trials as topic (4812) 4812
medical research (4804) 4804
risk (4792) 4792
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (274) 274
Online Resources - Online (46) 46
Collection Dvlpm't (Acquisitions) - Closed Orders (25) 25
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (17) 17
Collection Dvlpm't (Acquisitions) - Vendor file (16) 16
New College (Ivey) - Stacks (11) 11
Mt Sinai Hospital - Pathology (4) 4
OISE - Stacks (4) 4
UTL at Downsview - May be requested (4) 4
UofT at Scarborough - Stacks (4) 4
Lakeridge Health Sciences - Oshawa (3) 3
Scarborough Hospital - General (3) 3
UofT at Mississauga - Stacks (3) 3
Credit Valley Hospital - Stacks (2) 2
Humber River Regional Hospital - Finch Stacks (2) 2
Markham Stouffville Hospital - Stacks (2) 2
Robarts - Stacks (2) 2
Sunnybrook Health Sciences Centre - Sunnybrook Patient Education (2) 2
Baycrest Hospital - Resident/Client Library (1) 1
Credit Valley Hospital - Reference (1) 1
Credit Valley Hospital - Special Collections (1) 1
Gerstein Science - Circulation Desk (1) 1
Gerstein Science - Not Returned (1) 1
Gerstein Science - Reference (1) 1
Holland Bloorview Kids Rehabilitation - Stacks (1) 1
Humber River Regional Hospital - Church Stacks (1) 1
Humber River Regional Hospital - Finch Reference (1) 1
Media Commons - Audio Visual (1) 1
OISE - Children's Literature (1) 1
Providence Healthcare - Reference (1) 1
Scarborough Hospital - Birchmount (1) 1
Scarborough Hospital - Online (1) 1
St Josephs Health Centre - Stacks (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
St. Michael's Hospital - Stacks (1) 1
Thomas Fisher Rare Book - May be requested at Fisher (1) 1
Toronto East General Hospital - Reference (1) 1
Trinity College (John W Graham) - Storage (1) 1
University College (Laidlaw) - Stacks (1) 1
Women's College Hospital - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (124391) 124391
Japanese (1733) 1733
German (1320) 1320
French (1176) 1176
Chinese (542) 542
Russian (499) 499
Italian (383) 383
Spanish (304) 304
Polish (172) 172
Hungarian (101) 101
Dutch (97) 97
Portuguese (91) 91
Danish (83) 83
Czech (49) 49
Swedish (48) 48
Finnish (32) 32
Hebrew (32) 32
Korean (31) 31
Norwegian (29) 29
Bulgarian (17) 17
Serbian (15) 15
Croatian (14) 14
Turkish (10) 10
Romanian (9) 9
Ukrainian (7) 7
Slovak (5) 5
Lithuanian (3) 3
Bosnian (2) 2
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2012, ISBN 1846920663, 176
Book
Nature, ISSN 0028-0836, 2013, Volume 497, Issue 7447, pp. 108 - 112
Cancers acquire resistance to systemic treatment as a result of clonal evolution and selection(1,2). Repeat biopsies to study genomic evolution as a result of... 
HETEROGENEITY | LUNG-CANCER | ACTIVATION | EVOLUTION | VARIANTS | AXL | MULTIDISCIPLINARY SCIENCES | TAMOXIFEN RESISTANCE | TUMOR-CELLS | MUTATIONS | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Genomics | Humans | Ovarian Neoplasms - pathology | Lung Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Ovarian Neoplasms - genetics | Neoplasms - genetics | DNA Mutational Analysis | Female | Antineoplastic Agents - pharmacology | DNA, Neoplasm - analysis | Ovarian Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Intercellular Signaling Peptides and Proteins - genetics | Breast Neoplasms - drug therapy | Genome, Human - genetics | Neoplasms - drug therapy | Phosphatidylinositol 3-Kinases - genetics | Drug Resistance, Neoplasm - genetics | Exome - genetics | Breast Neoplasms - genetics | Class I Phosphatidylinositol 3-Kinases | Breast Neoplasms - pathology | Retinoblastoma Protein - genetics | Plasma - chemistry | Alleles | Carcinoma, Non-Small-Cell Lung - drug therapy | DNA, Neoplasm - genetics | Neoplasms - pathology | Mediator Complex Subunit 1 - genetics | Drug Resistance, Neoplasm - drug effects | Evolution, Molecular | Antimitotic agents | Care and treatment | Physiological aspects | Dosage and administration | Genetic aspects | Research | Nucleotide sequencing | Drug resistance | Antineoplastic agents | DNA sequencing | Blood plasma | Cancer | Plasma | Biopsy | Breast cancer | Genomes | Mutation | Patients | Deoxyribonucleic acid--DNA | Tumors | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 18, Issue 1, pp. 75 - 87
Summary Background Poly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian carcinomas with homologous recombination deficiency. Along with BRCA1... 
Hematology, Oncology and Palliative Medicine | BRCA MUTATION | POLY(ADP-RIBOSE) POLYMERASE | RANDOMIZED PHASE-2 | ONCOLOGY | HOMOLOGOUS RECOMBINATION DEFICIENCY | MUTANT-CELLS | PROSTATE-CANCER | INHIBITORS | DNA-REPAIR | NEGATIVE BREAST-CANCER | GENOMIC LOSS | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Germ-Line Mutation - genetics | Neoplasm Recurrence, Local - pathology | Ovarian Neoplasms - genetics | Neoplasms, Glandular and Epithelial - genetics | Peritoneal Neoplasms - drug therapy | Fallopian Tube Neoplasms - genetics | Female | Antineoplastic Agents - pharmacology | Poly(ADP-ribose) Polymerases - chemistry | Ovarian Neoplasms - drug therapy | Platinum - pharmacology | Fallopian Tube Neoplasms - drug therapy | Peritoneal Neoplasms - pathology | Neoplasms, Glandular and Epithelial - pathology | Fallopian Tube Neoplasms - pathology | Survival Rate | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | BRCA1 Protein - genetics | International Agencies | Peritoneal Neoplasms - genetics | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Indoles - therapeutic use | Neoplasm Recurrence, Local - genetics | Aged | Neoplasm Staging | BRCA2 Protein - genetics | Drug Resistance, Neoplasm - drug effects | Sugars | Monosaccharides | Ovarian cancer | Analysis | Carcinoma | Cancer | Index Medicus
Journal Article
Nature, ISSN 0028-0836, 11/2015, Volume 527, Issue 7579, pp. 472 - 476
The role of epithelial-to-mesenchymal transition (EMT) in metastasis is a longstanding source of debate, largely owing to an inability to monitor transient and... 
CANCER-CELLS | STEM-CELLS | THERAPY | MULTIDISCIPLINARY SCIENCES | RESISTANCE | INDUCTION | MODEL | MIR-200 FAMILY | EXPRESSION | BREAST | PLASTICITY | Lung Neoplasms - drug therapy | Apoptosis - drug effects | Antineoplastic Agents, Alkylating - pharmacology | Epithelial-Mesenchymal Transition - drug effects | Lung Neoplasms - pathology | Male | Epithelial-Mesenchymal Transition - genetics | Cyclophosphamide - therapeutic use | Mammary Neoplasms, Experimental - genetics | Cell Tracking | Lung Neoplasms - secondary | Neoplasm Metastasis - drug therapy | Mammary Neoplasms, Experimental - pathology | Female | Disease Models, Animal | Mammary Neoplasms, Experimental - drug therapy | Lung Neoplasms - genetics | Reproducibility of Results | Disease Progression | Antineoplastic Agents, Alkylating - therapeutic use | Cell Lineage | Neoplasm Metastasis - genetics | Drug Resistance, Neoplasm - genetics | Animals | Neoplasm Metastasis - pathology | Cyclophosphamide - pharmacology | Cell Proliferation - drug effects | Mice | MicroRNAs - genetics | Drug Resistance, Neoplasm - drug effects | Development and progression | Metastasis | Drug resistance | Cell differentiation | Health aspects | Lung cancer | Chemotherapy | Analysis | Stem cells | Cancer | Studies | Genotype & phenotype | Transgenic animals | Rodents | Morphology | Fibroblasts | Breast cancer | Cancer therapies | Tumors | Index Medicus
Journal Article
Nature Medicine, ISSN 1078-8956, 11/2015, Volume 21, Issue 11, pp. 1318 - 1325
Journal Article
EMBO Molecular Medicine, ISSN 1757-4676, 10/2014, Volume 6, Issue 10, pp. 1279 - 1293
Epithelial‐mesenchymal transition ( EMT ) is a reversible and dynamic process hypothesized to be co‐opted by carcinoma during invasion and metastasis. Yet,... 
drug response | microarray | gene expression signature | epithelial‐mesenchymal transition | prognosis | Drug response | Epithelial-mesenchymal transition | Prognosis | Microarray | Gene expression signature | MOLECULAR SUBTYPES | MEDICINE, RESEARCH & EXPERIMENTAL | GENE-EXPRESSION SIGNATURE | STEM-CELLS | GENOMIC ANALYSES | OVARIAN-CANCER | NEGATIVE BREAST-CANCER | CLINICAL-RELEVANCE | MICRORNA CONTROL | CLAUDIN-LOW | epithelial-mesenchymal transition | SIGNATURE PREDICTS RESISTANCE | Lung Neoplasms - drug therapy | Oligonucleotide Array Sequence Analysis | Colorectal Neoplasms - genetics | Humans | Epithelial-Mesenchymal Transition - drug effects | Antineoplastic Agents - therapeutic use | Epithelial-Mesenchymal Transition - genetics | Ovarian Neoplasms - genetics | Urinary Bladder Neoplasms - genetics | Neoplasms - genetics | Colorectal Neoplasms - drug therapy | Female | Gene Expression Regulation, Neoplastic - drug effects | Ovarian Neoplasms - drug therapy | Lung Neoplasms - genetics | Stomach Neoplasms - genetics | Treatment Outcome | Transcriptome - drug effects | Transcriptome - genetics | Stomach Neoplasms - drug therapy | Urinary Bladder Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Neoplasms - drug therapy | Disease-Free Survival | Breast Neoplasms - genetics | Cell Line, Tumor | Cancer patients | Chemotherapy | Patient outcomes | Stem cells | Development and progression | Drug therapy | Gene expression | Ovarian cancer | Cancer | Medical research | Breast cancer | Tumors | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2015, Volume 33, Issue 3, pp. 244 - 250
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2012, Volume 30, Issue 21, pp. 2654 - 2663
Purpose The frequency of BRCA1 and BRCA2 germ-line mutations in women with ovarian cancer is unclear; reports vary from 3% to 27%. The impact of germ-line... 
POLY(ADP-RIBOSE) POLYMERASE | CLEAR-CELL | ONCOLOGY | RESISTANCE | IMPROVED SURVIVAL | HOMOLOGOUS RECOMBINATION | CARCINOMA | CARRIERS | TUMORS | CHEMOTHERAPY | FEATURES | Medical History Taking | Recurrence | Prospective Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Drug Resistance, Neoplasm | Cystadenocarcinoma, Serous - genetics | Cystadenocarcinoma, Serous - drug therapy | Case-Control Studies | Ovarian Neoplasms - genetics | Peritoneal Neoplasms - drug therapy | Neoplasm Grading | Fallopian Tube Neoplasms - genetics | Aged, 80 and over | Genes, BRCA2 | Germ-Line Mutation | Adult | Female | Genes, BRCA1 | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Carcinoma - drug therapy | Carcinoma, Endometrioid - genetics | Kaplan-Meier Estimate | Mutation Rate | Treatment Outcome | Carcinoma, Endometrioid - drug therapy | Australia - epidemiology | Ovarian Neoplasms - epidemiology | Disease-Free Survival | Point Mutation | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Peritoneal Neoplasms - genetics | Carcinoma - genetics | Aged | Platinum Compounds - administration & dosage | Neoplasm Staging | Adenocarcinoma, Clear Cell - genetics | Adenocarcinoma, Clear Cell - drug therapy | Cohort Studies | Index Medicus | Original Reports | Gynecologic Cancer | Gync21 | Gync15
Journal Article
American Journal of Pathology, ISSN 0002-9440, 2010, Volume 177, Issue 4, pp. 1647 - 1656
Phosphatase and tensin homolog (PTEN) is a key modulator of trastuzumab sensitivity in HER2-overexpressing breast cancer. Because PTEN opposes the downstream... 
ADJUVANT CHEMOTHERAPY | CELLS | INHIBITION | THERAPY | HUMAN-BREAST-CANCER | MUTATIONS | PATHOLOGY | RECEPTORS | TRASTUZUMAB RESISTANCE | EXPRESSION | CARCINOMA | Lung Neoplasms - drug therapy | Receptors, Estrogen - metabolism | Receptor, ErbB-2 - genetics | Lung Neoplasms - mortality | Humans | Middle Aged | Bone Neoplasms - secondary | Antibodies, Monoclonal - therapeutic use | Immunoenzyme Techniques | Receptors, Progesterone - metabolism | Young Adult | Carcinoma, Ductal, Breast - drug therapy | Brain Neoplasms - mortality | Liver Neoplasms - secondary | Proto-Oncogene Proteins c-akt - metabolism | Carcinoma, Ductal, Breast - metabolism | PTEN Phosphohydrolase - genetics | Ribosomal Protein S6 Kinases, 70-kDa - metabolism | Survival Rate | Lymphatic Metastasis | Brain Neoplasms - drug therapy | Mutation - genetics | Breast Neoplasms - drug therapy | Class I Phosphatidylinositol 3-Kinases | Carcinoma, Lobular - metabolism | Trastuzumab | Bone Neoplasms - mortality | Phosphorylation | Prognosis | Receptor, ErbB-2 - metabolism | Phosphatidylinositol 3-Kinases - metabolism | Liver Neoplasms - mortality | Carcinoma, Ductal, Breast - mortality | Carcinoma, Lobular - mortality | Breast Neoplasms - metabolism | Antibodies, Monoclonal, Humanized | Brain Neoplasms - secondary | In Situ Hybridization | Lung Neoplasms - secondary | Adult | Female | Bone Neoplasms - drug therapy | Neoplasm Invasiveness | Liver Neoplasms - drug therapy | PTEN Phosphohydrolase - metabolism | Phosphatidylinositol 3-Kinases - genetics | Breast Neoplasms - mortality | Aged | Carcinoma, Lobular - drug therapy | Index Medicus | Abridged Index Medicus | Regular
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2012, Volume 366, Issue 26, pp. 2455 - 2465
Antibodies to PD-1 protein and to one of its ligands, PD-L1, have shown antitumor activity. Unleashing T cells from inhibitory signals may be a strategy to... 
MEDICINE, GENERAL & INTERNAL | LYMPHOCYTE-ASSOCIATED ANTIGEN-4 | SOLID TUMORS | RESPONSE CRITERIA | CELL ACTIVATION | IMMUNOTHERAPY | B7 FAMILY | ANTITUMOR IMMUNITY | CLINICAL ACTIVITY | PHASE-I | T-CELLS | Neoplasms - metabolism | Humans | Antibodies, Monoclonal - adverse effects | Programmed Cell Death 1 Receptor - metabolism | Antibodies, Monoclonal - therapeutic use | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Stomach Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Neoplasms - drug therapy | Dose-Response Relationship, Drug | Pancreatic Neoplasms - drug therapy | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Melanoma - drug therapy | Adult | Female | Carcinoma, Non-Small-Cell Lung - drug therapy | Programmed Cell Death 1 Receptor - immunology | Carcinoma, Renal Cell - drug therapy | Ovarian Neoplasms - drug therapy | Intravenous administration | Kidneys | Immune response | Disease | PD-1 protein | Tumor cells | Lung | Colorectal carcinoma | Body weight | Melanoma | Lymphocytes T | Breast cancer | Stomach cancer | Patients | Ovarian cancer | Pancreatic cancer | PD-L1 protein | Antitumor activity | Ligands | Autoimmune diseases | Gastric cancer | Clear cell-type renal cell carcinoma | Apoptosis | Tumors | Index Medicus | Abridged Index Medicus
Journal Article